For the quarter ending 2025-09-30, ZIVOW had $47,399 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 6,884,474 | - |
| Fair value adjustment - convertible debt | 1,754 | - |
| Non-cash lease expense | 85,373 | -14,828 |
| Prepaid expenses | - | -274,918 |
| Accounts receivable | - | -32,153 |
| Employee and director equity-based compensation | 26,959 | 937,288 |
| Other expenses related to extinguishment of colicense agreements | -1 | 2,738,282 |
| Prepaid expenses | 133,388 | - |
| Security deposits | 0 | - |
| Customer deposits | -19,364 | 34,364 |
| Accounts receivable | -2,211 | - |
| Accounts payable | 132,051 | 313,849 |
| Net loss | - | -5,851,418 |
| Accounts payable - related party | 263,061 | -124,706 |
| Lease liabilities | -84,899 | 29,818 |
| Accrued liabilities | 185,672 | 337,774 |
| Net cash (used in) operating activities | -266,556 | -1,906,648 |
| Net cash from investing activities | 0 | 0 |
| Proceeds from short term loan payable, other | 488,198 | - |
| Proceeds from private sales of common stock - related party | - | 50,000 |
| Payments on short term loan payable, other | 341,739 | - |
| Proceeds from private sales of common stock - other | - | 100,000 |
| Proceeds from convertible note and warrants | 250,000 | - |
| Payments of loans payable, other | - | -195,279 |
| Payment on note payable | 103,475 | - |
| Payment of term debt | - | 68,890 |
| Proceeds from private offering issuance | 100,000 | - |
| Proceeds of loans payable, other | - | 488,198 |
| Proceeds from private offering issuance - related party | 295,000 | - |
| Net cash provided by financing activities | 313,955 | 374,029 |
| Increase (decrease) in cash | 47,399 | -1,532,619 |
| Cash and cash equivalents at beginning of period | 1,542,442 | - |
| Cash and cash equivalents at end of period | 57,222 | - |
Zivo Bioscience, Inc. (ZIVOW)
Zivo Bioscience, Inc. (ZIVOW)